0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Kits > CTLA-4 > EP-117

B7-2 [Biotinylated] : CTLA-4 Inhibitor Screening ELISA Kit

For research use only.

Order Now

IDComponentsSize
EP117-C01High-bind Plate1 plate
EP117-C02Human CTLA-410 μg
EP117-C03Biotinylated Human B7-265 μg
EP117-C04Anti-CTLA-4 Neutralizing Antibody20 μg
EP117-C05Streptavidin-HRP10 μg
EP117-C06Coating Buffer12 mL
EP117-C0710xWashing Buffer 50 mL
EP117-C08Blocking Buffer50 mL
EP117-C09Substrate Solution24 mL
EP117-C10Stop Solution7 mL
  • Background
    Cytotoxic T lymphocyte associated ANTIgen-4 (CTLA-4), also known as CD152, is a kind of leukocyte differentiation antigen and a transmembrane receptor on T cells, sharing B7 ligand with CD28. The binding of CTLA-4 with B7 induces T cells to be non-reactive and participates in the negative regulation of immune response. The recombinant CTLA-4 Ig can effectively and specifically inhibit cellular and humoral immune responses in vivo and in vitro, and has significant therapeutic effects on transplant rejection and various autoimmune diseases with very low toxicity. It is considered as a promising new immunosuppressive drug at present.
  • Application

    This kit is developed for screening for inhibitors of human CTLA-4 binding to human B7-2.

    It is for research use only.

  • Reconstitution
    Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
  • Storage
    Unopened kit should be stored at 2°C -8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.

    The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.

  • Assay Principles
    This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new CTLA-4 pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human B7-2 to immobilized human CTLA-4 in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated B7-2 protein, a human CTLA-4 protein, an anti-CTLA-4 neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.

    Your experiment will include 4 simple steps:

    a) Coat the plate with human CTLA-4.

    b) Add your molecule of interest to the tests.

    c) Add human B7-2-Biotin to bind the coated human CTLA-4.

    d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.

    Finally, the ability of your compound to inhibit B7-2: CTLA-4 binding will be determined by comparing OD readings among different experimental groups.

Typical Data Please refer to Ds document for the assay protocol.
 CTLA-4 TYPICAL DATA

INHIBITION OF B7-2 [BIOTINYLATED]: CTLA-4 BINDING BY ANTI-CTLA-4 NEUTRALIZING ANTIBODY
Serial dilutions of Anti-CTLA-4 Neutralizing antibody (Catalog # EP117-C04) (1:1 serial dilution, from 10 μg/mL to 0.01μg/mL) was added into CTLA-4: Biotinylated B7-2 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

  • Clinical and Translational Updates

Comments (0)


Voraussichtlicher Liefertermin für vorrätige Produkte: 2 Arbeitstage

Price(EUR) : €660.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:3 Details
  • Number of Drugs in Clinical Trials:61 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop

Nachricht schicken